SCHEMBL4655748

SCHEMBL4655748

CCOC(=O)/C=C/c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.65
CA7 P43166 2/20 0.65
CA9 Q16790 2/20 0.65
CA14 Q9ULX7 2/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
ALDH1A1 P00352 3/20 0.63
LMNA P02545 3/20 0.63
MAPT P10636 3/20 0.63
THRB P10828 1/20 0.63
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
KMT2A Q03164 4/20 0.60
MEN1 O00255 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP3A4 P08684 1/20 0.57
SRD5A2 P31213 1/20 0.56
TTR P02766 1/20 0.56
DPP4 P27487 1/20 0.56
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4655750 1.00 CA12 (0.65) CA12CA7CA9CA14CA1
SCHEMBL20857445 0.89 CA12 (0.67) CA12CA7CA9CA14CA1
SCHEMBL6335525 0.89 CA12 (0.67) CA12CA7CA9CA14CA1
SCHEMBL6340119 0.88 CA12 (0.65) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL112445 0.87 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL1866942 0.87 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL112446 0.87 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL12001792 0.87 CA12 (0.72) CA12CA7CA9CA14CA1
SCHEMBL9643718 0.87 ALOX5 (0.62) CA12CA7CA9CA14CA1
SCHEMBL9643721 0.87 ALOX5 (0.62) CA12CA7CA9CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625207-A4 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS THERACOS INC (US) 2008-11-12 EP disclosed
US-20080188654-A1 Compounds for treatment of inflammation, diabetes and related disorders THERACOS, INC. (US) 2008-08-07 US disclosed
US-20080108825-A1 Compounds for treatment of inflammation, diabetes and related disorders THERACOS, INC. (US) 2008-05-08 US disclosed
US-20080103302-A1 Compounds for treatment of inflammation, diabetes and related disorders THERACOS, INC. (US) 2008-05-01 US disclosed
US-7323496-B2 Compounds for treatment of inflammation, diabetes and related disorders THERACOS, INC. (US) 2008-01-29 US disclosed
US-20070259961-A9 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS NEOGI PARTHA 2007-11-08 US disclosed
EP-1625207-A2 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS Theracos, Inc. (US) 2006-02-15 EP disclosed
WO-2004101752-A2 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS THERACOS, INC. (US) 2004-11-25 WO disclosed
EP-1448515-A2 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS Theracos, Inc. (US) 2004-08-25 EP disclosed
US-20040097593-A1 Compounds for treatment of inflammation, diabetes and related disorders SEED, BRIAN 2004-05-20 US disclosed
WO-2003048108-A2 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS THERACOS, INC (US) 2003-06-12 WO disclosed
US-6005116-A HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA SANKYO COMPANY, LIMITED (JP) 1999-12-21 US disclosed
EP-0885891-A1 ISOXAZOLE DERIVATIVES SANKYO COMPANY LIMITED (JP) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259961-A9 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS CPS1, ABAT, IL6 CA12 1306/4885CA7 645/4885CA9 405/4885
US-20080103302-A1 Compounds for treatment of inflammation, diabetes and related disorders CPS1, ABAT, IL6 CA12 1294/4885CA7 619/4885CA9 399/4885
US-20080108825-A1 Compounds for treatment of inflammation, diabetes and related disorders CPS1, ABAT, IL6 CA12 1294/4885CA7 619/4885CA9 399/4885
US-20040097593-A1 Compounds for treatment of inflammation, diabetes and related disorders CPS1, ABAT, IL6 CA12 1306/4885CA7 645/4885CA9 405/4885
US-20080188654-A1 Compounds for treatment of inflammation, diabetes and related disorders CPS1, ABAT, IL6 CA12 1294/4885CA7 619/4885CA9 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.